comparemela.com

Page 6 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

NEW YORK, April 4, 2024 /PRNewswire/  Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.

AbbVie acquisition signals confidence in small-cap biotech sector s growth potential

AbbVie acquisition signals confidence in small-cap biotech sector s growth potential
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Sweet Financial Partners LLC Purchases New Shares in Immunic, Inc (NASDAQ:IMUX)

Sweet Financial Partners LLC purchased a new stake in Immunic, Inc. (NASDAQ:IMUX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 29,829 shares of the company’s stock, valued at approximately $45,000. Sweet Financial Partners LLC owned 0.07% of Immunic at the […]

Immunic (IMUX) Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium

Immunic (IMUX) Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.